Figure 1.
Iron dose according to the intravenous iron indication.
The size of the dots corresponds to the number of patients receiving a given dose of intravenous iron. The most frequent indication for intravenous iron was chronic blood losses associated to liver disease. These patients also required the highest doses of intravenous iron.
Table 1.
Indication, mean dose, transfusion requirements and mortality according to the indication of intravenous iron.
Table 2.
Costs, including upper and lower bounds used in the sensitivity and Monte Carlo analysis.
Figure 2.
One-way sensitivity analysis: Influence of the staff cost/hour in the total cost per patient.
Incremental cost of iron sucrose over Ferric carboxymaltose increases as the staff costs increase.
Figure 3.
Two-way sensitivity analysis modifying costs of ferric carboxymaltose and iron sucrose.
The values in the table show that the incremental cost (€) per treated patient was favoured ferric carboxymaltose, unless if it cost more than €180 per 1000 mg and if cost of iron sucrose decreased simultaneously below €10 per 200 mg.
Figure 4.
Monte Carlo simulation after 10,000 iterations.
The bars show the number of iterations that resulted in a given incremental cost value. Values under 0 correspond to the simulations that favour the use of Iron sucrose. As shown by the figure, the model favoured the use of ferric carboxymaltose in 97% of the iterations.